Hjem › Kronisk lymfatisk leukæmi › New Jersey
Kronisk lymfatisk leukæmi kliniske forsøg i New Jersey
13 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i New Jersey.
Byer i New Jersey
Officiel studietekst (engelsk)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Jefferson Cherry Hill Hospital, Cherry Hill
- Sidney Kimmel Cancer Center Washington Township, Sewell
RekruttererFase 3
Alder 65 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Englewood Hospital and Medical Center, Englewood
- Hackettstown Medical Center, Hackettstown
- Morristown Medical Center, Morristown
- og 6 flere
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, Hackensack
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06542250Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Memorial Sloan Kettering Basking Ridge, Basking Ridge
- Cooper Hospital University Medical Center, Camden
- Jersey City Medical Center, Jersey City
- og 7 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Sidney Kimmel Comprehensive Cancer Center Washington Twp, Sewell
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06943872A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Titan Health Partners Llc Dba Astera Cancer Care, East Brunswick
- John Theurer Cancer Center Hackensack University Medical Center, Hackensack
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06973187A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0016), Hackensack
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Hackensack Meridian Health, Hackensack
- Carol G Simon Cancer Center, Morristown
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT07648264A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Hackensack
- Research Site, New Brunswick
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06564038Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Atlantic Health, Morristown
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT04588922A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Summit Medical Group, Florham Park
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 12. jun. 2026 · NCT07271667Study of SGR-1505 in Mature B-Cell Neoplasms
- Regional Cancer Care Associates, Hackensack
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Regional Cancer Care Associates /ID# 244620, Hackensack
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 9. feb. 2026 · NCT04895436Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.